Abdul-Ghani M, Maffei P, DeFronzo RA (2024) Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes. Lancet Diabetes Endocrinol 12(9):674–680

Article  CAS  PubMed  Google Scholar 

Montaigne D, Butruille L, Staels B (2021) PPAR control of metabolism and cardiovascular functions. Nat Reviews Cardiol 18(12):809–823

Article  CAS  Google Scholar 

Moller D, Berger J (2003) Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes 27(3):S17–S21

Article  CAS  Google Scholar 

Małodobra-Mazur M, Ołdakowska M, Dobosz T (2024) Exploring PPAR Gamma and PPAR Alpha’s Regulation Role in Metabolism via Epigenetics Mechanism. Biomolecules 14(11):1445

Article  PubMed  PubMed Central  Google Scholar 

Nakamura A, Kagaya Y, Saito H, Kanazawa M, Sato K, Miura M, Kondo M, Endo H (2024) Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome. Heart Vessels 39(6):486–495

Article  PubMed  Google Scholar 

Komiyama Y, Tamaki N, Tsuji K, Mori N, Mashiba T, Ochi H, Kobashi H, Ogawa C, Nonogi M, Yoshida H et al (2025) Effect of Pemafibrate on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Multicenter Study. JGH Open 9(9):e70277

Article  PubMed  PubMed Central  Google Scholar 

Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ et al (2022) Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med 387(21):1923–1934

Article  PubMed  Google Scholar 

Velingkar A, Vuree S, Prabhakar PK, Kalashikam RR, Banerjee A, Kondeti S (2023) Fibroblast growth factor 21 as a potential master regulator in metabolic disorders. Am J Physiology-Endocrinology Metabolism 324(5):E409–E424

Article  CAS  Google Scholar 

Suzuki T, Sato T, Tanaka M, Nakata K, Endo K, Aida H, Kawaharata W, Hosaka I, Umetsu A, Ogawa T (2025) Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus. Front Endocrinol 16:1496671

Article  Google Scholar 

Nomoto H, Kito K, Iesaka H, Oe Y, Kawata S, Tsuchida K, Yanagiya S, Miya A, Kameda H, Cho KY (2023) Favorable effect of pemafibrate on insulin resistance and β-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D study. Pharmaceutics 15(7):1838

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, Suganami H, Araki E (2018) Effects of a novel selective peroxisome proliferator-activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. J Diabetes Invest 9(6):1323–1332

Article  CAS  Google Scholar 

Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart J-C, Kodama T (2016) Group K–S: Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: a randomized, double blind, active-and placebo-controlled, phase 2 trial. Atherosclerosis 249:36–43

Article  CAS  PubMed  Google Scholar 

Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S (2021) Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo‐controlled clinical trials. Cardiovasc Diabetol 20(1):96

Article  CAS  PubMed  PubMed Central  Google Scholar 

Booth A, Mitchell AS, Mott A, James S, Cockayne S, Gascoyne S, McDaid C (2020) An assessment of the extent to which the contents of PROSPERO records meet the systematic review protocol reporting items in PRISMA-P. F1000Research 9

Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA (2019) Assessing risk of bias in a randomized trial. Cochrane Handb Syst reviews interventions 205–228

Schwingshackl L, Knüppel S, Schwedhelm C, Hoffmann G, Missbach B, Stelmach-Mardas M, Dietrich S, Eichelmann F, Kontopantelis E, Iqbal K et al (2016) Perspective: NutriGrade: A Scoring System to Assess and Judge the Meta-Evidence of Randomized Controlled Trials and Cohort Studies in Nutrition Research. Adv Nutr 7(6):994–1004

Article  PubMed  PubMed Central  Google Scholar 

Higgins J (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www cochrane-handbook org

Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5(1):13

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

Article  PubMed  PubMed Central  Google Scholar 

Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

Article  CAS  PubMed  PubMed Central  Google Scholar 

Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y (2018) Effects of pemafibrate, a novel selective PPARα modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 41(3):538–546

Article  CAS  PubMed  Google Scholar 

16 (2026) Diabetes Care in the Hospital: Standards of Care in Diabetes—2026. Diabetes Care 49(Supplement1):S339–S355

Google Scholar 

Mohamed DA-W, Elayat WM, Abozeid AA, Abdel-Salam MF, Teama NM, Abdelrahim DS, Tamim YM (2021) Glucose transporter 4 and peroxisome proliferator-activated receptor-alpha overexpression association with cardioprotective effects of myoinositol and metformin combination in type 2 diabetic rat model. J Endocrinol Metabolism 11(5):140–151

Article  Google Scholar 

Izumihara R, Nomoto H, Kito K, Yamauchi Y, Omori K, Shibayama Y, Yanagiya S, Miya A, Kameda H, Cho KY (2024) Switching from conventional fibrates to pemafibrate has beneficial effects on the renal function of diabetic subjects with chronic kidney disease. Diabetes Metabolism J 48(3):473–481

Article  Google Scholar 

Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA et al (2005) FGF-21 as a novel metabolic regulator. J Clin Investig 115(6):1627–1635

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V et al (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabol 5(6):415–425

Article  CAS  Google Scholar 

Fruchart J-C (2017) Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol 16(1):124

Article  PubMed  PubMed Central  Google Scholar 

Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98(19):2088–2093

Article  CAS  PubMed  Google Scholar 

Murakami K, Sasaki Y, Asahiyama M, Yano W, Takizawa T, Kamiya W, Matsumura Y, Anai M, Osawa T, Fruchart JC et al (2022) Selective PPARα modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis. Cells 11(4):720

Sasaki Y, Asahiyama M, Tanaka T, Yamamoto S, Murakami K, Kamiya W, Matsumura Y, Osawa T, Anai M, Fruchart JC et al (2020) Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. Sci Rep 10(1):7818

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31(8):1473–1478

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38(32):2459–2472

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatanaka T, Kosone T, Saito N, Takakusagi S, Tojima H, Naganuma A, Takagi H, Uraoka T, Kakizaki S (2021) Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score. JGH Open 5(10):1183–1189

Article  PubMed  PubMed Central  Google Scholar 

Shinozaki S, Tahara T, Lefor AK, Ogura M (2020) Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. Clin experimental Hepatol 6(3):270–274